Serine protease inhibitors

1. A compound selected from the group consisting of:

2. A pharmaceutical composition comprising a compound of claim 1 .

3. A method of inhibiting a serine protease in a subject, the method comprising administering to the subject a compound of Formula (I) in an amount effective to inhibit the serine protease:

wherein:

m is an integer selected from the group consisting of 1 and 2;

A, Q, and R are each carbon;

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 ,and R 9 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, alkoxyl, hydroxyl, hydroxyalkyl, carboxyl, acyl, including —COOR 10 , wherein R 10 is lower alkyl, carbonyl, carbamoyl, alkylcarbamoyl, halogen, amino, nitro, nitrile, amide, haloalkyl, aryl, cycloalkyl, aralkyloxyl, and —SO 3 H;

R 7 is selected from the group consisting of:

and a pharmaceutically acceptable salt, or solvate thereof.

4. The method of claim 3 , wherein R 1 -R 6 and are each independently selected from the group consisting of t-butyl, Cl, Br, methyl, —OCH 3 , —NO 2 , —NH 2 , —OH, —CH 2 OH, —CHO, —COOH, —COOCH 3 , —COOCH 2 CH 3 , —CF 3 , —CONHCH 3 , —C≡N, —CONH 2 , H, F, isopropyl, phenyl, cyclohexyl, benzyloxyl, and —SO 3 H.

5. The method of claim 3 , wherein the compound of Formula (I) is selected from the group consisting of:

6. The method of claim 3 , wherein the serine protease is selected from the group consisting of chymase, trypsin, tryptase, chymotrypsin, elastase, thrombin, plasmin, kallikrein, Complement C1, acrosomal protease, lysosomal protease, cocoonase, α-lytic protease, protease A, protease B, serine carboxypeptidase II, subtilisin, urokinase, Factor VIIa, Factor IXa, and Factor Xa.

7. The method of claim 6 , wherein the serine protease is chymase.

8. A method for treating a serine protease-associated disease in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I):

wherein:

m is an integer selected from the group consisting of 1 and 2;

A, Q, and R are carbon;

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 9 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, alkoxyl, hydroxyl, hydroxyalkyl, carboxyl, acyl, including —COOR 10 , wherein R 10 is lower alkyl, carbonyl, carbamoyl, alkylcarbamoyl, halogen, amino, nitro, nitrile, amide, haloalkyl, aryl, cycloalkyl, aralkyloxyl, and —SO 3 H;

R 7 is selected from the group consisting of:

and a pharmaceutically acceptable salt, or solvate thereof.

9. The method of claim 8 , wherein R 1 -R 6 are each independently selected from the group consisting of t-butyl, Cl, Br, methyl, —OCH 3 , —NO 2 , —NH 2 , —OH, —CH 2 OH, —CHO, —COOH, —COOCH 3 , —COOCH 2 CH 3 , —CF 3 , —CONHCH 3 , —C≡N, —CONH 2 , H, F, isopropyl, phenyl, cyclohexyl, benzyloxyl, and —SO 3 H.

10. The method of claim 8 , wherein the compound of Formula (I) is selected from the group consisting of:

11. The method of claim 8 , wherein the serine protease-associated disease is a chymase-associated disease.

12. The method of claim 11 , wherein the chymase-associated disease is selected from the group consisting of asthma, allergic rhinitis, fibrosis, hypertension, cardiac hypertrophy, heart failure, rheumatoid arthritis, diabetic nephropathy, chronic obstructive pulmonary disease (COPD), an inflammatory disease, urticaria, atopic dermatitis, allergic conjunctivitis, mastocytosis, scleroderma, atherosclerosis, myocardial ischemia, myocardial infarction, restenosis after percutaneous transluminal coronary angioplasty (PTCA), restenosis after bypass graft surgery, ischemic peripheral circulatory disorders, hyperaldosteronism, diabetic retinopathy, nephritis, glomerulosclerosis, renal insufficiency, psoriasis, solid tumor, postoperative adhesion, glaucoma, ocular hypertension, hypercardia, diabetic or non-diabetic renal disease, ischemic re-perfusion disorder, keloid, psoriasis, solid tumors, and pulmonary hypertension.

13. The method of claim 11 , wherein the chymase-associated disease comprises a cardiovascular disease.

14. The method of claim 13 , wherein the cardiovascular disease comprises a cardiac or circulatory system disease due to abnormal exacerbation of angiotensin II (Ang II) production.

15. The method of claim 13 , wherein the cardiovascular disease is selected from the group consisting of cardiac insufficiency, hypercardia, a stasis cardiac disease, hypertension, arteriosclerosis, a peripheral circulatory disorder, revasoconstriction after PCTA, a diabetic renal disorder, a non-diabetic renal disorders, myocardial infarction, angioendothelia, vascular disorders accompanying arterialization or atheroma, and a repair of organs affected by stroke.

16. The method of claim 8 , further comprising administering a second therapeutic agent in combination with the compound of Formula (I).

17. The method of claim 16 , wherein the second therapeutic agent is selected from the group consisting of an angiotensin I-converting enzyme (ACE) inhibitor, an alpha-adrenergic blocker, a central adrenergic inhibitor, a beta-adrenergic blocker, an angiotensin II receptor blocker, a calcium channel blocker, a vasodilator, a phosphodiesterase (PDE) inhibitor, an HMG-CoA reductase inhibitor, a cholesterol-lowering agent, an antiarrhythmic agent, a digitalis drug, a nitrate, a diuretic, an anticoagulant, an antiplatelet, a thrombolytic agent, and combinations thereof.

18. The method of claim 16 , wherein the second therapeutic agent is selected from the group consisting of a CETP inhibitor/apoA1 mimetic, an adenosine diphosphate (P2Y12) inhibitor, an aldosterone antagonist, a factor Xa inhibitor, a natriuretic peptide (ANP/BNP), a renin inhibitor, a Rho kinase inhibitor, a Lipoprotein-associated phospholipase A2 inhibitor, a cardiac glycoside, a fibrate, an Endothelin Receptor Antagonist, a GPIIb/IIIa inhibitor, a histone deacetylase inhibitor, a nicotinic acid derivative, a vasopeptidase inhibitor, a nitrite, a fatty acid oxidation inhibitor, an acyl-CoA:cholesterol acyltransferase inhibitor, a microsomal triglyceride transfer protein inhibitor, a thiazolidinedione, a adenosine receptor modulator, a cholesterol absorbtion inhibitor, an Advanced Glycation End product/receptor (AGE/RAGE) interaction modulator/blocker, a dipyridamole, a gene therapy, a cell therapy, and combinations thereof.

19. The method of claim 16 , wherein the second therapeutic agent is administered sequentially, simultaneously, or a combination thereof, with a compound of Formula (I).